Influence of vaccination schedules and host factors on antibody response following hepatitis B vaccination
- PMID: 1396753
- DOI: 10.1007/BF01962073
Influence of vaccination schedules and host factors on antibody response following hepatitis B vaccination
Abstract
In a prospective multicentre trial, the influence of schedule, compliance, age, sex and weight on the antibody response to hepatitis B vaccination was investigated. Comparison of the vaccination schedules 0, 1, 6 months (group 1; n = 143) and 0, 1, 2, 12 months (group 2; n = 141) was performed in months 3, 7 and 12. In addition, the antibody response was compared one month after the third and one and six months after the last vaccination. Seroprotection rates (anti-HBs greater than 10 IU/l) and antibody titres, given as geometric means (GMTs), were higher in group 1 at month 12 as well as one month after completion of three immunizations. More vaccinees of group 2, however, showed seroprotection at month 3 with higher GMTs. In addition, GMTs in group 2 were higher both one month and six months after the last vaccine dose. Determination of parallel corrected correlation factors demonstrated that age was the most important single factor, followed by body weight and sex. However, no more than 3% of the variation in the GMT can be explained by the influence of age. Due to decreased compliance with the four-dose schedule with a drop-out rate of approximately 10% of the vaccinees, the total percentage of initial vaccinees who in the end developed protective antibody levels was higher in the 0, 1, 6 months schedule. Thus, it can be concluded that subjects likely to comply will benefit from the 0, 1, 2, 12 months schedule as more rapid protection is obtained and the higher antibody levels after the booster vaccination at month 12 provide longer protection. However, vaccinees whose compliance might be questionable over a period of 12 months, should be selected for the vaccination 0, 1, 6 months schedule as compliance is at a higher level over this period and advantage can be taken of the booster effect of the third dose given in month 6.
Similar articles
-
Comparison of a triple antigen and a single antigen recombinant vaccine for adult hepatitis B vaccination.J Med Virol. 2001 Jul;64(3):290-8. doi: 10.1002/jmv.1049. J Med Virol. 2001. PMID: 11424117 Clinical Trial.
-
Comparison of two immunization schedules with recombinant hepatitis B vaccine and natural immunity acquired by hepatitis B infection in dialysis patients.Vaccine. 1994;12(3):223-34. doi: 10.1016/0264-410x(94)90198-8. Vaccine. 1994. PMID: 8165854 Clinical Trial.
-
Persistence of anti-HBs antibody and immunological memory in children vaccinated with hepatitis B vaccine at birth.J Ayub Med Coll Abbottabad. 2006 Oct-Dec;18(4):4-9. J Ayub Med Coll Abbottabad. 2006. PMID: 17591001
-
Schedules for hepatitis B vaccination of risk groups: balancing immunogenicity and compliance.Sex Transm Infect. 2007 Oct;83(6):426-32. doi: 10.1136/sti.2006.022111. Sex Transm Infect. 2007. PMID: 17911142 Free PMC article. Review.
-
Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.Drugs. 2003;63(10):1021-51. doi: 10.2165/00003495-200363100-00006. Drugs. 2003. PMID: 12699402 Review.
Cited by
-
Factors That Influence the Immune Response to Vaccination.Clin Microbiol Rev. 2019 Mar 13;32(2):e00084-18. doi: 10.1128/CMR.00084-18. Print 2019 Mar 20. Clin Microbiol Rev. 2019. PMID: 30867162 Free PMC article. Review.
-
Determinants of effective vaccine coverage in low and middle-income countries: a systematic review and interpretive synthesis.BMC Health Serv Res. 2017 Sep 26;17(1):681. doi: 10.1186/s12913-017-2626-0. BMC Health Serv Res. 2017. PMID: 28950899 Free PMC article.
-
Timing of primary three-dose hepatitis B vaccination and postvaccination serologic testing among a large cohort of healthy adults.J Med Virol. 2022 Sep;94(9):4433-4439. doi: 10.1002/jmv.27848. Epub 2022 May 17. J Med Virol. 2022. PMID: 35538595 Free PMC article.
-
Hepatitis B vaccination schedules in genitourinary medicine clinics.Genitourin Med. 1996 Jun;72(3):210-2. doi: 10.1136/sti.72.3.210. Genitourin Med. 1996. PMID: 8707326 Free PMC article.
-
Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases.Bioessays. 2012 Dec;34(12):1050-9. doi: 10.1002/bies.201200099. Epub 2012 Sep 26. Bioessays. 2012. PMID: 23012250 Free PMC article.